Grifols Gets FDA OK for Xembify® for Primary Immunodeficiencies

– Xembify® is Grifols’ first 20% subcutaneous immunoglobulin for the treatment of primary immunodeficiencies

– Grifols is a frontrunner in disease treatment with immunoglobulins, and this approval will enable the company to further expand its portfolio of plasma-derived medicines to benefit of patients and healthcare professionals

– Xembify® represents a significant R+D+i milestone for Grifols and an important step forward in its long-term sustainable growth strategy

– The company plans to launch Xembify® in the United States in the last quarter of the year and is working to obtain additional approvals in Canada, Europe and other global markets

https://www.prnewswire.com/news-releases/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies-300880234.html